NYSE · MRK
Merck & Company, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for MRK has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $2.12 | $2.20 | $2.01 | 5 |
| Dec 2026 | $1.90 | $2.01 | $1.77 | 4 |
| Mar 2027 | $2.45 | $2.45 | $2.45 | 1 |
| Jun 2027 | $2.40 | $2.40 | $2.40 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · Fintel · RTTNews · Zacks- BNK Invest · 2 h agoDow Movers: GOOGL, HONIVIn early trading on Thursday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst performing Dow component thus far
- Fintel · 3 h agoMerck & Co., Inc. Announces Third-Quarter 2026 Financial ResultsMerck & Co., Inc. announced its third-quarter 2026 financial results, reporting total worldwide sales of $18.1 Billion, which represents 5% growth. For the third quarter of 2026, Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $2
- RTTNews · 6 h agoMerck Boosts FY26 Outlook – Update(RTTNews) – While reporting financial results for the third quarter on Thursday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, raised its adjusted earnings and net sales guidance for the full-year 2026.
- RTTNews · 6 h agoMerck & Co Inc. Q3 Income Retreats(RTTNews) – Merck & Co Inc. (MRK) released a profit for third quarter that Drops, from the same period last year
- Zacks · 6 h agoMerck (MRK) Surpasses Q3 Earnings and Revenue EstimatesMerck (MRK) delivered earnings and revenue surprises of +17.45% and +4.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · 7 h agoMerck & Co Q3 26 Earnings Conference Call At 9:00 AM ET(RTTNews) – Merck & Co Inc. (MRK) will host a conference call at 9:00 AM ET on October 29, 2026, to discuss Q3 26 earnings results.
- The Motley Fool · 8 h agoCould Revolution Medicines Be a Millionaire-Maker Stock?Revolution Medicines' stock has soared over 9x in three years.
- Zacks · Oct 27, 10:50 AM EDTGilead to Report Q3 Earnings: How Should You Play the Stock Now?Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant caution.
- MarketBeat · Oct 27, 10:20 AM EDTMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid?Merck & Co. (NYSE: MRK) and Moderna (NASDAQ: MRNA) just cleared a bar no cancer vaccine had cleared before. Their personalized melanoma vaccine succeeded in a Phase 3 trial. Adding intismeran autogene to Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone.
- Zacks · Oct 27, 9:47 AM EDTWhat's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
- Zacks · Oct 27, 9:00 AM EDTPfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 7:56 AM EDTIs Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?MRK heads into Q3 earnings with strong Keytruda sales and new drug growth, but declining estimates, Gardasil weakness and looming patent risks cloud its outlook.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Merck & Company, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.